• PEY14 BIMATOPROST, LATANOPROST, AND TRAVOPROST FOR THE TREATMENT OF GLAUCOMA-A COST-EFFECTIVENESS ANALYSIS IN SCANDINAVIA USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

    Nov 1, 2006, 00:00

  • POB10 RIMONABANT IMPROVES HEALTH-RELATED QUALITY OF LIFE IN OVERWEIGHT/OBESE PATIENTS WITH TYPE 2 DIABETES- RIO-DIABETES STUDY

    Nov 1, 2006, 00:00

  • PCV62 DRUG USE EVALUATION OF ROSUVASTATIN IN A HONG KONG PUBLIC HOSPITAL

    Nov 1, 2006, 00:00

  • PDB16 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES- COST UTILITY ANALYSIS IN A FRENCH GOVENMENT PAYER SETTING

    Nov 1, 2006, 00:00

  • PCV36 A HEALTH ECONOMIC EVALUATION OF CONCOMITANT SURGICAL ABLATION FOR ATRIAL FIBRILLATION

    Nov 1, 2006, 00:00

  • PCN1 THE EPIDEMIOLOGIC, HEALTH-RELATED QUALITY OF LIFE, AND ECONOMIC BURDEN OF GASTROINTESTINAL STROMAL TUMORS

    Nov 1, 2006, 00:00

  • IN2 EUROPEAN SURVEILLANCE OF ANTIMICROBIAL CONSUMPTION (ESAC)- DEVELOPING VALID ANTIBIOTIC PRESCRIBING QUALITY INDICATORS FOR AMBULATORY CARE

    Nov 1, 2006, 00:00

  • MC3 USING SIMULATIONS TO EXPLORE THE INFLUENCE OF COMPETING RISK ON TREATMENT-EFFECT

    Nov 1, 2006, 00:00

  • PR4 PREFERENCES OF PEOPLE WITH DIABETES FOR INHALED AND INJECTABLE INSULIN REGIMENS

    Nov 1, 2006, 00:00

  • PCN25 TREATMENT OF ACTINIC KERATOSIS (AK) AND BASAL CELL CARCINOMA (BCC) WITH METVIX® (MAL-PDT) IN REAL LIFE PRACTICE- A COST OF ILLNESS AND MODEL VALIDATION STUDY

    Nov 1, 2006, 00:00

  • PMH44 TRAJECTORIES OF PATIENT AND CLINICIAN REPORTED ANTIPSYCHOTIC COMPLIANCE IN THE SOHO STUDY AND THEIR CAUSES AND CONSEQUENCES

    Nov 1, 2006, 00:00

  • PHP8 ANTIBIOTIC UTILIZATION IN NIS REGION OF SERBIA AND MONTENEGRO

    Nov 1, 2006, 00:00

  • RS1 CAN PHARMACEUTICAL INDUSTRY USE REPS TO PROVIDE MEDICAL PRACTICE GUIDELINES? (MIGRAINE AND ASTHMA)

    Nov 1, 2006, 00:00

  • PDB11 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF REPAGLINIDE VERSUS NATEGLINIDE IN COMBINATION WITH METFORMIN IN TYPE 2 DIABETES PATIENTS FAILING MONOTHERAPY IN THE SWEDISH SETTING

    Nov 1, 2006, 00:00

  • PDB31 REIMBURSEMENT OF PHARMACEUTICALS AND BRANDGENERIC DRUG UTILIZATION- EVIDENCE FROM ORAL HYPOGLYCEMIC AGENTS FOR AMBULATORY CARE IN TAIWAN

    Nov 1, 2006, 00:00

  • PMH39 USE OF VERBALLY ADMINISTERED AND VERBALLY ORIENTING SCALES TO IMPROVE DATA COLLECTION

    Nov 1, 2006, 00:00

  • PAA4 PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS

    Nov 1, 2006, 00:00

  • PRS9 CLINICAL PRACTICE VS GOLD RECOMMENDATIONS IN THE MANAGEMENT OF COPD PATIENTS- AN ECONOMIC ANALYSIS OF THE LACK OF ADHERENCE TO GUIDELINES

    Nov 1, 2006, 00:00

  • PEN4 EVALUATION OF THE ASSOCIATION BETWEEN THE QUALITY OF LIFE, SOCIAL CLASS AND HEIGHT IN THE GENERAL ADULT UK POPULATION

    Nov 1, 2006, 00:00

  • PEY7 MODELLING THE HEALTH ECONOMIC IMPACT OF OLOPATADINE COMPARED TO BRANDED AND GENERIC SODIUM CROMOGLYCATE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN THE UK

    Nov 1, 2006, 00:00

  • PIH11 EXPENDITURES ON PHARMACEUTICALS- DEMOGRAPHIC CHANGE AND INNOVATION-AN EMPIRICAL ANALYSIS

    Nov 1, 2006, 00:00

  • PAA10 HEALTH PLAN STRUCTURE AND EXPENDITURES FOR ASTHMA CARE

    Nov 1, 2006, 00:00

  • POS7 COST-EFFECTIVENESS OF RISEDRONATE VS. GENERIC ALENDRONATE- CONSIDERATION OF CALCIUM SUPPLEMENTS

    Nov 1, 2006, 00:00

  • PDB15 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES- COST UTILITY ANALYSIS IN AN ITALIAN SETTING

    Nov 1, 2006, 00:00

  • PHP24 THE COST OF ILLNESS- SPAIN 1980–2000

    Nov 1, 2006, 00:00

  • PMH34 IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN SCHIZOPHRENIC PATIENTS SWITCHED TO RISPERIDONE LONG-ACTING INJECTION (RLAI)

    Nov 1, 2006, 00:00

  • PR1 HEALTH RELATED QUALITY OF LIFE IN DIFFERENT STATES OF BREAST CANCER

    Nov 1, 2006, 00:00

  • PCV16 MAIN CARDIOVASCULAR RISK FACTORS- ASSOCIATION AND CONTROL IN A PRIMARY HEALTH CARE SETTING

    Nov 1, 2006, 00:00

  • PCV2 CARDIOVASCULAR RISK FACTORS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • PSK7 CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF GENERIC AND DISEASE-SPECIFIC INSTRUMENTS USED IN CHILDREN WITH ATOPIC DERMATITIS

    Nov 1, 2006, 00:00

  • OA1 QUALITY OF LIFE IN EARLY RHEUMATOID ARTHRITIS TREATED WITH COMBINATION VS. SINGLE DRUG THERAPY-RESULTS FROM FIN-RACO TRIAL

    Nov 1, 2006, 00:00

  • HP4 SUMMARIZING POPULATION HEALTH USING EQ-5D

    Nov 1, 2006, 00:00

  • POB7 THE RELATIONSHIP BETWEEN WEIGHT CHANGES AND RELATED CHANGES IN HEALTH-RELATED UTILITY- EVIDENCE OF CAUSE AND AFFECT

    Nov 1, 2006, 00:00

  • PCN56 OUTCOME VALIDATION OF A SUCCINCT HPV INFECTION MODEL FOR FRANCE

    Nov 1, 2006, 00:00

  • PHP1 DESTINATION- FOREIGN PROVIDER (MEDICAL TOURISM FOR THE GERMAN PATIENT)

    Nov 1, 2006, 00:00

  • PCV35 ESTIMATING LIFETIME COSTS AND LIFE EXPECTANCY ASSOCIATED WITH CARDIOVASCULAR DISEASE IN A SWISS POPULATION WITH AND WITHOUT METABOLIC SYNDROME

    Nov 1, 2006, 00:00

  • PIN6 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS MORE COST-EFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN GERMANY

    Nov 1, 2006, 00:00

  • DB4 SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES- COST UTILITY ANALYSIS IN A UNITED STATES THIRD-PARTY PAYER SETTING

    Nov 1, 2006, 00:00

  • PCV88 MEDICATION TREATMENT PATTERNS FOR DYSLIPIDEMIA IN US

    Nov 1, 2006, 00:00

  • PCN69 HEALTH UTILITIES IN THE UK FOR SECOND LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PRIOR CHEMOTHERAPY

    Nov 1, 2006, 00:00

  • PCV77 DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS

    Nov 1, 2006, 00:00

  • PHP22 NUTRICORE®- COST-EFFECTIVENESS-ANALYSIS (CE) OF AN EVIDENCE BASED CLINICAL NUTRITION CONCEPT IN CORRELATION WITH RELEVANT CLINICAL OUTCOMES IN HOSPITALIZED MALNOURISHED PATIENTS BY RISKADJUSTMENT OF DIAGNOSIS BASED SEVERITY OF DISEASE ...

    Nov 1, 2006, 00:00

  • PEY5 COMPARISON OF PHYSICIAN AND PATIENT-REPORTED OUTCOMES OF ADULTS WITH DRY EYE DISEASE (KERATOCONJUNCTIVITIS SICCA) MANAGED OVER TIME IN A PATIENT REGISTRY

    Nov 1, 2006, 00:00

  • PEY10 COST-EFFECTIVENESS OF TWO TREATMENT SEQUENCES IN GLAUCOMA TREATMENT- XALATAN®-XALACOM® VERSUS TRAVATAN®-DUOTRAV®

    Nov 1, 2006, 00:00

  • POB9 DEVELOPMENT OF A NEW QUESTIONNAIRE FOR IDENTIFING PREDICTIVE FACTORS INFLUENCING WEIGHT LOSS THERAPIES

    Nov 1, 2006, 00:00

  • PDB37 SCORING AND PSYCHOMETRIC VALIDATION OF A SCALE FOR DIABETIC PATIENT PROFILING BASED ON PATIENT ATTITUDE TOWARDS INSULIN

    Nov 1, 2006, 00:00

  • PCV21 ANTIHYPERTENSIVE DRUG BUDGET IMPACT OF THE ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN THE UK

    Nov 1, 2006, 00:00

  • PDB30 DRUGS USE IN DIABETIC PATIENTS

    Nov 1, 2006, 00:00

  • PRS10 PREVALENCE OF PULMONARY HYPERTENSION IN GERMANY–ESTIMATIONS BASED ON A TOP-DOWN APPROACH

    Nov 1, 2006, 00:00

  • PIN3 COST–EFFECTIVNESS ANALYSIS OF TONSILOPHARYNGITIS AND RHYNOPHARINGITIS ACCUTA, ANTIBIOTIC TREATMANT, SRBIJA, NIS REGION

    Nov 1, 2006, 00:00

  • PIN15 CHRONIC HEPATITIS B (CHB) MANAGEMENT COSTS IN SWEDEN

    Nov 1, 2006, 00:00

  • POS17 BASELINE CHARACTERISTICS OF FRENCH POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)

    Nov 1, 2006, 00:00

  • PUK24 LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q), OVERACTIVE BLADDER SHORT FORM QUESTIONNAIRE (OAB-Q SF), AND OAB ASSESSMENT TOOL (OAB-V8) IN 4 LANGUAGES

    Nov 1, 2006, 00:00

  • PAA6 VALUING REDUCED RATES OF OROPHARYNGEAL ADVERSE EVENTS- COMPARISON OF CICLESONIDE WITH FLUTICASONE PROPIONATE

    Nov 1, 2006, 00:00

  • SZ3 PREDICTORS OF GAF CHANGES IN AUSTRALIANS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONGACTING INJECTION (RLAI)- INTERIM RESULTS FROM THE E-STAR STUDY

    Nov 1, 2006, 00:00

  • Erratum

    Sep 1, 2006, 00:00

  • Eliciting Stated Preferences for Health-Technology Adoption Criteria Using Paired Comparisons and Recommendation Judgments

    Sep 1, 2006, 00:00

  • Cost-Effectiveness of Olanzapine as a First-Line Treatment- A Comment

    Sep 1, 2006, 00:00

  • Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version

    Sep 1, 2006, 00:00

  • Cost-Effectiveness of Olanzapine as a First-Line Treatment- A Response to Comment

    Sep 1, 2006, 00:00

  • Implantable or External Defibrillators for Individuals at Increased Risk of Cardiac Arrest- Where Cost-Effectiveness Hits Fiscal Reality

    Sep 1, 2006, 00:00

  • Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States

    Sep 1, 2006, 00:00

  • Analytic Considerations in Economic Evaluations of Multinational Cardiovascular Clinical Trials

    Sep 1, 2006, 00:00

  • A Dollar Is a Dollar Is a Dollar—or Is It?

    Sep 1, 2006, 00:00

  • Development of a Smiling Touchscreen Multimedia Program for HRQoL Assessment in Subjects with Varying Levels of Literacy

    Sep 1, 2006, 00:00

  • Analyses of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled Trials

    Sep 1, 2006, 00:00

  • Indirect Costs and Cost-Effectiveness Analysis

    Jul 1, 2006, 00:00

  • Are Australians Able to Access New Medicines on the Pharmaceutical Benefits Scheme in a More or Less Timely Manner? An Analysis of Pharmaceutical Benefits Advisory Committee Recommendations, 1999–2003

    Jul 1, 2006, 00:00

  • Probabilistic Analysis and Computationally Expensive Models- Necessary and Required?

    Jul 1, 2006, 00:00

  • An Economic Evaluation of Two Ototopical Treatments for Acute Otitis Media in Tympanostomy Tube Patients

    Jul 1, 2006, 00:00

  • Applying the Grid Computation in Long-Term Retrospective Health Insurance Data Analysis

    Jul 1, 2006, 00:00

  • Is Rosuvastatin Really a More Efficient Therapeutic Option than Atorvastatin?

    Jul 1, 2006, 00:00

  • Comparing the EQ-5D and the SF-6D Descriptive Systems to Assess Their Ceiling Effects in the US General Population

    Jul 1, 2006, 00:00

  • Managing Meningococcal Disease in the United States- Hospital Case Characteristics and Costs by Age

    Jul 1, 2006, 00:00

  • Fraction of Nursing Home Admissions Attributable to Urinary Incontinence

    Jul 1, 2006, 00:00

  • Trends in the Measurement of Health Utilities in Published Cost-Utility Analyses

    Jul 1, 2006, 00:00

  • Estimating the Cost-Effectiveness of Fluticasone Propionate for Treating Chronic Obstructive Pulmonary Disease in the Presence of Missing Data

    Jul 1, 2006, 00:00

  • Formulary Decision-Making Should Rely on the Best Available Evidence

    Jul 1, 2006, 00:00

  • POS14 HOME AUTOMATED TELEMANAGEMENT IN POST-HIP FRACTURE REHABILITATION

    May 1, 2006, 00:00

  • PNL27 THE EFFECT OF ADHERENCE TO ALZHEIMER'S DISEASE TREATMENT ON HEALTH CARE COSTS IN MANAGED CARE

    May 1, 2006, 00:00

  • FP1 USE OF MEDICATION COVERAGE METHODOLOGY IN MEASUREMENT OF PATIENT COMPLIANCE WITH PHARMACOTHERAPY

    May 1, 2006, 00:00

  • PIN12 LIFETIME MEDICAL COST OF CHRONIC HEPATITIS B

    May 1, 2006, 00:00

  • PPN2 IMPACT OF BACK PAIN ON ABSENTEEISM, PRODUCTIVITY LOSS, AND DIRECT HEALTH CARE COSTS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2006, 00:00

  • PMH22 ANTIPSYCHOTIC POLYPHARMACY COSTS-A FIVE-STATE MEDICAID STUDY

    May 1, 2006, 00:00

  • PHP23 EFFECT OF INSURANCE TYPE ON HEALTH PLANS' SPENDING ON SPECIALTY PHARMACEUTICALS- AN EMPIRICAL ANALYSIS

    May 1, 2006, 00:00

  • PPN1 OPIOID ASSOCIATED ERECTILE DISFUNCTION IN CHRONIC PAIN PATIENTS

    May 1, 2006, 00:00

  • PRS3 COMBINATION THERAPY [LONG ACTING BETA AGONISTS (LABA) PLUS INHALED CORTICOSTEROIDS] VERSUS LABA ALONE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE- AN ECONOMIC ANALYSIS

    May 1, 2006, 00:00

  • PMH8 COST-EFFECTIVENESS OF VENLAFAXINE- A CANADIAN PERSPECTIVE

    May 1, 2006, 00:00

  • PMC14 PREVAILING JUDGMENTS ABOUT SOCIETY'S WILLINGNESS TO PAY FORA QALY- DO THEY VARY BY COUNTRY? HAVE THEY CHANGED OVERTIME?

    May 1, 2006, 00:00

  • PAR2 ACTIVE SAFETY SURVEILLANCE FORTU-HUO-CHI-SHENG-TANG- A CHINESE HERBAL PRODUCT USED IN TREATIN OSTEOARTHRITIS OF KNEE

    May 1, 2006, 00:00

  • PIN22 USE OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING WITH MONTE CARLO SIMULATION TO REDUCE ANTIBIOTIC EXPENDITURES WITHOUT COMPROMISING PREDICTED EFFICACY

    May 1, 2006, 00:00

  • PAR1 PRESCRIPTION FOR LONGER LIFE- A DIAGNOSIS OF OSTEOARTHRITIS?

    May 1, 2006, 00:00

  • PCV45 RELIABILITY AND VALIDITY OF TAIWAN VERSION OF TREATMENT-RELATED QUALITY OF LIFE QUESTIONNAIRE FOR PATIENTS RECEIVING ORAL ANTICOAGULATION

    May 1, 2006, 00:00

  • PIN6 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXICOLATE FOR THE PRIMARY TREATMENT OF INVASIVE ASPERGILLOSIS

    May 1, 2006, 00:00

  • PIH10 THE TRANSLATION AND CULTURAL ADAPTATION OF AN ADOLESCENT SEXUAL BEHAVIOUR QUESTIONNAIRE

    May 1, 2006, 00:00

  • PIN23 A REVIEW OF HERD EFFECTS IN THE ECONOMIC EVALUATION OF CHILDHOOD VACCINATIONS

    May 1, 2006, 00:00

  • PMC11 DEVELOPMENT OF A GLOBAL HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER- CALIBRATION TO THE UNITED KINGDOM AND NETHERLANDS

    May 1, 2006, 00:00

  • PGI15 PRIOR AUTHORIZATION AND THE APPROPRIATE PRESCRIBING OF TEGASEROD- A LOOK AT A MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PDB3 EARLY HEALTH TECHNOLOGY ASSESSMENT- CONTINUOUS GLUCOSE MONITORING FOR THE MAINTENANCE OF GLYCEMIC CONTROL IN INSULIN-REQUIRING TYPE I DIABETES

    May 1, 2006, 00:00

  • PMH36 VARIATIONS IN THE OPERATIONAL DEFINITION OF MOOD DISORDERS IN RETROSPECTIVE CLAIMS DATABASE STUDIES

    May 1, 2006, 00:00

  • PHP7 THE DECISION TO CONDUCT A HEAD-TO-HEAD COMPARATIVE TRIAL- A GAME-THEORETIC ANALYSIS

    May 1, 2006, 00:00

  • PCN40 THE IMPACT OF HUMAN PAPILLOMAVIRUS INFECTION AND CERVICAL CANCER ON HEALTH-RELATED QUALITY OF LIFE- A REVIEW OF VALIDATED INSTRUMENTS CURRENTLY AVAILABLE

    May 1, 2006, 00:00

  • ND2 EVALUATIONS OF THE PRESCRIBED DAILY DOSES OF TRANSDERMAL FENTANYL AND TRANSDERMAL BUPRENORPHINE IN CANCERAND NON-CANCER PATIENTS IN GERMANY- RESULTS FROM A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2006, 00:00

  • PMH17 RESOURCE-USE AND COSTS ASSOCIATED WITH PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE

    May 1, 2006, 00:00

  • PDB11 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF REPAGLINIDE + METFORMIN VERSUS NATEGLINIDE + METFORMIN IN TYPE 2 DIABETES PATIENTS WITH INADEQUATE GLYCEMIC CONTROL ON MONOTHERAPY- A FINNISH ANALYSIS

    May 1, 2006, 00:00

  • PMS3 COMPARISON OF HOSPITAL COST WITH DRG REIMBURSEMENT RATE IN PATIENTS WITH PERITROCHANTERIC FRACTURE ACCORDING TO SURGICAL METHODS

    May 1, 2006, 00:00

  • PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES- RESULTS FROM A COMPUTERIZED SIMULATION MODEL

    May 1, 2006, 00:00

  • PMS1 HEALTH TECHNOLOGY ASSESSMENT- EXTRACORPOREAL SHOCKWAVE THERAPY (ESWT) FOR THE TREATMENT OF CHRONIC PLANTAR FASCIITIS

    May 1, 2006, 00:00

  • PG13 MAJOR GI EVENTS AMONG ELDERLY CHRONIC USERS OF COX-2SAND NON-SELECTIVE NSAIDS, WITH/WITHOUT ASPIRIN

    May 1, 2006, 00:00

  • CV2 IMPACT OF VENTRICULAR ARRHYTHMIA ON MORTALITY, HEALTH CARE UTILIZATION AND COST IN HOSPITALIZED ACUTE MYOCARDIAL INFARCTION PATIENTS

    May 1, 2006, 00:00

  • PR6 VALIDATION OF THE WORK PRODUCTIVITY QUESTIONNAIRE- RESULTS OF THE MATRIX STUDY

    May 1, 2006, 00:00

  • PRS7 TREATING DOCTOR AND DIRECT COSTS OF HOSPITALIZATION DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS

    May 1, 2006, 00:00

  • PNL17 ECONOMIC COSTS OF CHRONIC PRIMARY INSOMNIA IN THE UNITED STATES

    May 1, 2006, 00:00

  • PCV23 AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT) IN BRAZIL

    May 1, 2006, 00:00

  • PHP16 THE IMPACT OF THE PHARMACY AND THERAPEUTICS COMMITTEE ON THE PATIENTS'ACCESS TO PRESCRIPTION DRUGS IN THE SAUDI MINISTRY OF HEALTH- EXPLORATORY AND COMPARISON STUDY

    May 1, 2006, 00:00

  • PDB9 PHARMACOECONOMIC ANALYSIS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN TYPE II DIABETICS

    May 1, 2006, 00:00

  • PAS2 DRUG ADVERSE EVENTS MODIFYTHE TREATMENT AND COMPLIANCE OF ASTHMA PATIENTS

    May 1, 2006, 00:00

  • PIH18 EXPLORATORY FACTOR ANALYSIS OF A 13 ITEM BPH PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE (BPH-PSTQ)

    May 1, 2006, 00:00

  • Cost of Hypoglycemia in Patients with Type 2 Diabetes in Sweden

    May 1, 2006, 00:00

  • PMS2 THE COST-EFFECTIVENESS OF EXTRACORPOREAL SHOCK WAVE THERAPY FOR THE TREATMENT OF CHRONIC PLANTAR FASCIITIS

    May 1, 2006, 00:00

  • PRS9 EVALUATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS INITIATING AN INHALED CORTICOSTEROID OR AN ANTICHOLINERGIC INA MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PCV21 COSTS OF DIAGNOSTIC PROCEDURES OF INTERVENTIONIST CARDIOLOGY IN THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)

    May 1, 2006, 00:00

  • PHP11 PRESCRIPTION PATTERNS OF POTENTIALLY INAPPROPRIATE MEDICATIONS AMONG OLDER MEDICARE MANAGED CARE BENEFICIARIES

    May 1, 2006, 00:00

  • PNL25 FAILURE OF REGRESSION ADJUSTMENT AGAINST PROPENSITY SCORE MATCHING

    May 1, 2006, 00:00

  • PDB22 RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDY WITH PROPENSITY SCORE METHODS- CAN THEIR RESULTS CONVERGE?—A CASE STUDY IN ESTIMATING MARGINAL EFFECT OF INSULIN REGIMENS ON THE REDUCTION OF HEMOGLOBIN AIC AMONG PATIENTS WITH TYPE ...

    May 1, 2006, 00:00

  • PRS4 LIFETIME COSTS AND IMPACT ON LIFE EXPECTANCY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE U.S.- PROJECTIONS FROM A DECISION-ANALYTIC MODEL

    May 1, 2006, 00:00

  • HP2 THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS IN AN EMPLOYED POPULATION

    May 1, 2006, 00:00

  • PUK7 FACTORS INFLUENCING EARLY NEPHROLOGY CARE PRIOR TO HEMODIALYSIS INITIATION AMONG ELDERLY PATIENTS WITH END-STAGE RENAL DISEASE

    May 1, 2006, 00:00

  • AC3 DETERMINANTS OF NON-COMPLIANCE WITH BISPHOSPHONATE THERAPY IN WOMEN WITH POST-MENOPAUSAL OSTEOPOROSIS

    May 1, 2006, 00:00

  • PAS12 TREATMENT PERSISTENCE AND COMPLIANCE WITH MEDICATIONS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2006, 00:00

  • PCN17 EVALUATING THE COST OF CARE FOR EARLY AND LATE STAGE OROPHARYNGEAL CANCER IN THE CALIFORNIA MEDICAID POPULATION

    May 1, 2006, 00:00

  • Linguistic Validation of the US Spanish Work Productivity and Activity Impairment Questionnaire, General Health Version

    May 1, 2006, 00:00

  • PGI18 A NEW APPROACH TO USING SELF-REPORTED UTILIZATION TO ESTIMATE COST ASSOCIATED WITH MILD, MODERATE, AND SEVERE GERD-RELATED SYMPTOMS

    May 1, 2006, 00:00

  • PDB20 BLOOD GLUCOSE MONITORING RECOMMENDATIONS AND PRACTICES IN PATIENTS WITH TYPE 2 DIABETES- A SURVEY OF HEALTH CARE PROFESSIONALSAND PATIENTS IN THE UK

    May 1, 2006, 00:00

  • PEY4 EVALUATION OF DIRECT MEDICAL COST OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN PATIENTS IN THE MEDICARE POPULATION

    May 1, 2006, 00:00

  • PCV20 MARKOV-BASED ECONOMIC ANALYSIS OF NESIRITIDE IN ACUTE DECOMPENSATED HEART FAILURE

    May 1, 2006, 00:00

  • PCN25 REAL WORLD DOSING OF ERYTHROPOIETIC AGENTS IN A NATIONWIDE SAMPLE OF PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY- RESULTS FROM A LARGE RETROSPECTIVE OBSERVATIONAL STUDY

    May 1, 2006, 00:00

  • PNL15 COST-OF-ILLNESS FOR ADULTS WITH PARTIAL EPILEPSY IN SWEDEN

    May 1, 2006, 00:00

  • PCN24 DEFINING GUIDELINES ON BRCA MUTATION TESTING AT A MEDICAL ONCOLOGY UNIT—AT AN UNIVERSITY HOSPITAL IN SOUTH-EASTERN BRAZIL

    May 1, 2006, 00:00

  • POS10 TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PATIENTS WITH PAGET'S DISEASE TREATED WITH RISENDRONATE

    May 1, 2006, 00:00

  • PCV37 SURVEY OF PHYSICIAN ATTITUDES AND PRACTICES IN LIPID LOWERING MANAGEMENT

    May 1, 2006, 00:00

  • PCV54 DETERMINANTS OF TREATMENT PERSISTENCE INA GERMAN HYPERTENSIVE POPULATION

    May 1, 2006, 00:00

  • PMH40 ATYPICAL ANTIPSYCHOTIC COMPLIANCE AND PERSISTENCE AND ASSOCIATED HEALTH CARE UTILIZATION IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • POT3 COST OF HOSPITALIZATIONS FOR ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS PRE-AND POST-REPEAL OF THE UNIVERSAL HELMET LAW IN FLORIDA

    May 1, 2006, 00:00

  • PCV61 DETERMINANTS OF ADHERENCE TO STATINS INA MEDICAID MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PDB26 ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT DIABETES—A METHODOLOGICAL COMPARISON USING A CLAIMS DATABASE

    May 1, 2006, 00:00

  • PIH3 COST-EFFECTIVENESS ANALYSIS OF ORAL PHARMACOLOGICAL TREATMENTS OF ERECTILE DYSFUNCTION

    May 1, 2006, 00:00

  • POS8 PRICE AND UTILIZATION OF OSTEOPOROSIS MEDICATIONS IN U.S. MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • PNL7 COST-EFFICACY ANALYSIS OF MULTIPLE SCLEROSIS THERAPIES- ASSESSING THE IMPACT OF NEUTRALIZING ANTIBODIES

    May 1, 2006, 00:00

  • PMC3 HOW MUCH DOES A DAY IN THE HOSPITAL COSTÏ

    May 1, 2006, 00:00

  • PDB24 EFFECTS OF INDUCING CORRELATION AMONG CHOLESTEROL PARAMETERS ON OUTCOMES IN SIMULATION OF PHARMACEUTICAL EFFECTIVENESS

    May 1, 2006, 00:00

  • PCV7 A PROSPECTIVE STUDY EVALUATING STREPTOKINASE THERAPY ON CLINICAL OUTCOMES AND COSTS IN PATIENTS WITH MYOCARDIAL INFARCTION AT A TERTIARY CARE REFERRAL HOSPITAL IN KERALA, INDIA

    May 1, 2006, 00:00

  • PRO4 PREVALENCE OF MEDICATION COMPLIANCE AND PERSISTENCY WITH SPECIALTY MEDICATIONS IN MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PAS8 IMPROVING ASTHMA SELF-MANAGEMENT AND PATIENT OUTCOMES USING AN AUTOMATED PROGRAM

    May 1, 2006, 00:00

  • PUK9 ESTIMATING A PREFERENCE-BASED INDEX FROM A CONDITION SPECIFIC MEASURE-THE KING'S HEALTH QUESTIONNAIRE

    May 1, 2006, 00:00

  • PCV6 MODELED ACHIEVEMENT OF OPTIMAL LIPID VALUES WITH EXTENDED-RELEASE NIACIN/LOVASTATIN VERSUS SIMVASTATIN/EZETIMIBE COMBINATION THERAPY IN AT-RISK PATIENTS

    May 1, 2006, 00:00

  • PNL20 HEALTH CARE ECONOMIC BENCHMARKS FOR MULTIPLE SCLEROSIS IN A COMMERCIAL MANAGED CARE ENVIRONMENT

    May 1, 2006, 00:00

  • PDB17 MODELING THE COST-UTILITY OF REDUCED HYPOGLYCEMIA ANDWEIGHT GAIN AMONG TYPE 2 DIABETES PATIENTS NEWLY INITIATED ON BASAL INSULIN- A CASE STUDY OF DETEMIRAND NPH

    May 1, 2006, 00:00

  • POB3 COST-UTILITY ANALYSIS OF RIMONABANT IN THE TREATMENT OF OBESITY

    May 1, 2006, 00:00

  • PG12 DOSE-RESPONSE RELATION OF INTERFERON-ALPHA IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B- META-ANALYSIS AND META-REGRESSION OF RANDOMIZED TRIALS

    May 1, 2006, 00:00

  • Economic Evaluation in Health Care- The Point of View of Informed Physicians

    May 1, 2006, 00:00

  • The Future of Health Economic Modeling- Have We Gone Too Far or Not Far Enough?

    May 1, 2006, 00:00

  • PCV26 PRESCRIBING PATTERNS FOR ANTIHYPERTENSIVE DRUGS AFTERTHE PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) IN REGION EMILIA ROMAGNA (RER), ITALY

    May 1, 2006, 00:00

  • PCN34 VALIDATION OF AN INTERNET-BASED PATIENT HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE- DATA FROM CAPSURE

    May 1, 2006, 00:00

  • PNL6 EXAMINATION OF THE COST-EFFECTIVENESS OF DOPAMINE AGONISTS FORTHETREATMENT OF RESTLESS LEGS SYNDROME

    May 1, 2006, 00:00

  • PDB29 IMPACT OF TYPE OF PHARMACY (CHAIN VERSUS INDEPENDENT) ON MEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES- A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2006, 00:00

  • HI1 ADULT ECONOMIC STATUS AND OBESITY IN THE UNITED STATES- 2000-2002

    May 1, 2006, 00:00

  • ID2 OUTCOMES ASSOCIATED WITH ANTIFUNGAL DRUG SWITCHING IN PATIENTS WITH SERIOUS CANDIDA INFECTIONS

    May 1, 2006, 00:00

  • HP3 DETERMINANTS OF GENERIC ENTRY IN LAST DECADE

    May 1, 2006, 00:00

  • PIN14 DIRECT MEDICAL COSTS OF PATIENTS WITH HIV/AIDS IN MEXICO

    May 1, 2006, 00:00

  • PHP12 MEDICINE PRICES, AVAILABILITY AND AFFORDABILITY IN RAJASTHAN, INDIA

    May 1, 2006, 00:00

  • MH1 NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDERAND USE OF STIMULANTS AMONG CHILDREN IN THE UNITED STATES, 1993-2003

    May 1, 2006, 00:00

  • PCV12 ASSESSMENT OF THE EFFECTS OF ROFECOXIB, CELECOXIB AND NAPROXEN ON BLOOD PRESSURE AND CARDIOVASCULAR RISK- A RETROSPECTIVE CHART REVIEW STUDY

    May 1, 2006, 00:00

  • POT1 INCIDENCE AND ECONOMIC IMPACT ANALYSIS OF HYPONATREMIA IN HOSPITALIZED PATIENTS

    May 1, 2006, 00:00

  • PHM1 COST-EFFECTIVENESS OF ONCE-DAILY ORAL CHELATION THERAPY WITH DEFERASIROX VERSUS INFUSIONAL DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS

    May 1, 2006, 00:00

  • HI4 IMPACT OF PATIENT SELECTION CRITERIA AND MODEL SPECIFICATION ON COMPARISONS OF ALTERNATIVE THERAPIES-THE CASE OF ATYPICAL ANTIPSYCHOTICS

    May 1, 2006, 00:00

  • PRO2 SELF-REPORTED HEALTH STATUS PREDICTORS OF MEDICATION ADHERENCE IN OLDER ADULTS WITH CHRONIC DISEASES

    May 1, 2006, 00:00

  • PHP21 CALCULATION OF LORENZ CONCENTRATION CURVES AND GINI COEFFICIENT OF HEALTH EXPENDITURES IN HUNGARY

    May 1, 2006, 00:00

  • PDB38 A LITERATURE REVIEW OF TREATMENT SATISFACTION, ADHERENCE AND QOL INSTRUMENTS USED IN TYPE I AND 2 DIABETES

    May 1, 2006, 00:00

  • PMC19 EVALUATING THE STRENGTH OF EVIDENCE OF CHANGE- A QUALIFIED CHANGE VS SIMPLE DIFFERENCE APPROACH TO QUALITY OF LIFE RATINGS

    May 1, 2006, 00:00

  • PNL5 ASSESSING ABSOLUTE REDUCTIONS IN CLINICAL EFFECT- A MODEL FOR COMPARING THE COST-EFFECTIVENESS OF DISEASE MODIFYING DRUGS (DMDS) UTILIZED IN THE TREATMENT OF MULTIPLE SCLEROSIS (MS)

    May 1, 2006, 00:00

  • PIN3 THE COST OF TREATING RIBAVIRIN-INDUCED ANEMIA IN HEPATITIS C- THE IMPACT OF USING RECOMBINANT HUMAN ERYTHROPOETIN

    May 1, 2006, 00:00

  • Health Resource Utilization and Medical Care Cost of Acute Care Elderly Unit Patients

    May 1, 2006, 00:00

  • PGI10 COST OF ILLNESS IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE

    May 1, 2006, 00:00

  • PCN21 4D LOCALIZATION SYSTEM WITH TRANSPONDERS FOR CONTINUOUS TARGET LOCALIZATION FOR SET-UP AND TRACKING DURING RADIATION THERAPY- EARLY HEALTH TECHNOLOGY ASSESSMENT

    May 1, 2006, 00:00

  • PCV38 INITIAL PHARMACEUTICAL TREATMENT OF SIMPLE HYPERTENSION

    May 1, 2006, 00:00

  • PMH21 HEALTH CARE RESOURCE UTILIZATION AND COST OF BIPOLAR I DISORDER WITH AND WITHOUT PSYCHOTIC SYMPTOMS

    May 1, 2006, 00:00

  • PMC12 THE COST-EFFECTIVENESS OF BIOLOGIC AGENTS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS- A STRUCTURED REVIEW OF THE LITERATURE

    May 1, 2006, 00:00

  • PAS1 LEAVING AGAINST MEDICAL ADVICE (LAMA) IN ASTHMA EXACERBATION- CHARACTERISTICS AND DETERMINANTS OF LEAVERS

    May 1, 2006, 00:00

  • PCN1 ESTIMATING THE EFFECTIVENESS OF EARLY-STAGE LUNG CANCER ADJUVANT TREATMENTS IN PRACTICE USING INSTRUMENTAL VARIABLE METHODS

    May 1, 2006, 00:00

  • PMH3 AUSTRALIAN SCHIZOPHRENIC PATIENTS TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)- INTERIM RESULTS FROM THE E-STAR STUDY

    May 1, 2006, 00:00

  • PCV65 PATIENT ADHERENCE WITH ANTIDIABETIC, ANTIHYPERTENSIVE, AND LIPID-LOWERING MEDICATIONS- EVALUATION OF VETERANS WITH TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PSK3 “HEALTH BENEFIT LIMITS” LIMIT TREATMENT OF PSORIASIS AND OTHER DERMATOLOGICAL CONDITIONS

    May 1, 2006, 00:00

  • PIH12 SURVEY ASSESSMENT OF TREATMENT COMPLIANCE AND MEDICATION TAKING BEHAVIOR IN BENIGN PROSTATIC HYPERPLASIA

    May 1, 2006, 00:00

  • PR3 RACIAL DIFFERENCES IN PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE ASSESSMENT

    May 1, 2006, 00:00

  • PHM2 ECONOMIC AND QUALITY OF LIFE BURDEN OF HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA

    May 1, 2006, 00:00

  • PHP1 A COMPARISON OF CLINICAL TRIAL PARTICIPANTS TO THE GENERAL PATIENT POPULATION

    May 1, 2006, 00:00

  • PSM2 EFFECT OF SMOKING ON PERCEIVED HEALTH STATUS

    May 1, 2006, 00:00

  • PAR7 MODELLING OF THE COST-EFFECTIVENESS OF RITUXIMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY

    May 1, 2006, 00:00

  • PNL8 ASSESSING THE COST-EFFECTIVENESS OF IMMUNOMODULATORYTHERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM DATA

    May 1, 2006, 00:00

  • PNL23 CONTROLLING SELECTION BIAS ON CONTINUOUS VARIABLES

    May 1, 2006, 00:00

  • PMC16 GENERAL HEALTH STATUS AND PATIENT SATISFACTION- ARE THEY MUTUALLY EXCLUSIVE OR CORRELATED OUTCOMES?

    May 1, 2006, 00:00

  • PDB33 THE RELATIONSHIP BETWEEN HEALTH RELATED QUALITY OF LIFE (HRQOL)AND PAIN RESPONSE IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)

    May 1, 2006, 00:00

  • PMH31 LIKELIHOOD OF EMPLOYMENT TERMINATION FOR EMPLOYEES WITH BIPOLAR DISORDER TREATED WITH DIFFERENT PSYCHOTROPIC MEDICATIONS

    May 1, 2006, 00:00

  • PAS7 COMPUTERIZED DECISION SUPPORT FOR ASTHMA MANAGEMENT

    May 1, 2006, 00:00

  • PCN43 A SYSTEMATIC REVIEW OF THE EORTC QLQ-BR23- DESCRIPTIVE HEALTH RELATED QUALITY OF LIFE INSTRUMENT USED IN BREAST CANCER

    May 1, 2006, 00:00

  • PNL28 STUDYING DISCONTINUATION, SWITCHING, AND AUGMENTATION USING COMPETING RISK METHODS

    May 1, 2006, 00:00

  • POB5 THE IMPACT OF BODY MASS INDEX ON HEALTH-RELATED QUALITY OF LIFE AMONG US ADULTS

    May 1, 2006, 00:00

  • PIH16 WHAT EXPECTATIONS DO MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH) HAVE FOR TREATMENT?

    May 1, 2006, 00:00

  • PMC4 THE LEVEL OF AWARENESS OFTMC PHYSICIANS ON THE PRICES OF COMMONLY PRESCRIBED MEDICATIONS AND DIAGNOSTIC PROCEDURES AND ITS EFFECT ON THEIR PRESCRIBING PREFERENCES

    May 1, 2006, 00:00

  • PIN16 CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN ACUTE HOSPITALS- A PREVALENT COST ISSUE

    May 1, 2006, 00:00

  • HE3 DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES

    May 1, 2006, 00:00

  • PCV1 USING ANTI-COAGULANTS AS PROPHYLAXIS FOR DVT/PE

    May 1, 2006, 00:00

  • PUK8 ONE SOLUTION TO THREE PROBLEMS

    May 1, 2006, 00:00

  • PG14 COMPARATIVE EFFICACY OF LAMIVUDINE WITH ADEFOVIR IN PATIENTS WITH HBEAG POSITIVE AND NEGATIVE CHRONIC HEPATITIS B- DIRECT AND INDIRECT META-ANALYSIS

    May 1, 2006, 00:00

  • PDB32 A SYSTEMATIC REVIEW OF ADHERENCE WITH DIABETES TREATMENT AND THE IMPACT OF NON-ADHERENCE ON HEALTH CARE COSTS

    May 1, 2006, 00:00

  • PUK6 EVALUATING THE OUTCOME AND COST ASSOCIATED WITH ATAMSULOSIN REAUTHORIZATION PROGRAM

    May 1, 2006, 00:00

  • PCV36 RATE OF LOW-DENSITY LIPOPROTEIN (LDL) GOAL ATTAINMENT WITH LIPID LOWERING THERAPIES AT A LI PID CLINIC IN A PUBLIC HOSPITAL OF HONG KONG—POSSIBLE ROLE OF A CLINICAL PHARMACY SERVICE

    May 1, 2006, 00:00

  • PCN22 THE EFFECT OF EFFICIENCY OF ACCESS TO CARE

    May 1, 2006, 00:00

  • PIN17 A COST-UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A VERSUS PEGINTERFERON ALFA-2B AS THE INITIAL TREATMENT OF HEPATITIS C FROM THE PERSPECTIVE OF THE VETERANS AFFAIRS HEALTH CARE SYSYTEM

    May 1, 2006, 00:00

  • PHP13 ENHANCING THE SAFETY OF OTC MEDICATION USE FOR HISPANIC CONSUMERS WITH BILINGUAL LABELS

    May 1, 2006, 00:00

  • PMH14 BURDEN OF ILLNESS OF ALZHEIMER'S PATIENTS IN COMMERCIAL MANAGED CARE

    May 1, 2006, 00:00

  • PCN19 COLONOSCOPYAND FLEXIBLE SIGMOIDOSCOPY- A MICROCOSTING STUDY EVALUATING DIAGNOSTIC PROCEDURAL COSTS IN AN OUTPATIENT ENDOSCOPY CLINIC

    May 1, 2006, 00:00

  • PUK10 PSYCHOMETRIC PROPERTIES OF THE KING'S HEALTH QUESTIONNAIRES SYSTEMATIC CRITICAL APPRISAL OF THE LITERATURE

    May 1, 2006, 00:00

  • PRS1 SURVIVAL AMONG COPD PATIENTS USING FLUTICASONE/SALMETEROL IN COMBINATION VERSUS OTHER INHALED STEROIDS AND BRONCHDIALATORS ALONE

    May 1, 2006, 00:00

  • POB8 IMPACT OF ABDOMINAL OBESITY ON QUALITY OF LIFE

    May 1, 2006, 00:00

  • PAS3 ECONOMIC EVALUATION OF SYMBICORT® (BUDESONIDE/FORMOTEROL) SINGLE-INHALER MAINTENANCE AND RELIEVERTHERAPY (SMART) IN ASTHMA

    May 1, 2006, 00:00

  • PDB14 MODELLING THE EFFECTIVENESS OF ORAL AGENTS IN ACHIEVING HBAICAND LIPID TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    May 1, 2006, 00:00

  • PCN44 IMPROVEMENT IN SENSORY PAIN RATING AFTER PALLIATIVE RADIONUCLIDE THERAPY IN PATIENTS WITH ADVANCED PROSTATE CANCER

    May 1, 2006, 00:00

  • PPN5 ADVANCES IN PAIN MEASUREMENT- ITEM RESPONSE THEORY (IRT) BASED METHODS AND THE PAIN IMPACT QUESTIONNAIRE (PIQ-6)

    May 1, 2006, 00:00

  • PCV39 PREDICTING ANTIHYPERTENSIVE DRUG UTILIZATION- AN APPLICATION OF LATENT CLASS MODELS

    May 1, 2006, 00:00

  • PCN38 PROPENSITY SCORE MATCHING WITH LIMITED OVERLAP

    May 1, 2006, 00:00

  • PAR8 USING MABTHERA IN PATIENTS WITH RHEUMATIC ARTHRITIS IN SPAIN- RESULTS OF COST-EFFECTIVENESS DATA BASED ON MICRO-SIMULATION

    May 1, 2006, 00:00

  • PCV17 DECISION ANALYSIS TO COMPARE THE COST-EFFECTIVENESS OF THE STATINS AVAILABLE BY PRESCRIPTION VERSUS OVER THE COUNTER BASED FROM A SOCIETAL PERSPECTIVE

    May 1, 2006, 00:00

  • PIH9 TEXAS COMMUNITY PHARMACISTS'WILLINGNESS TO ACCEPT PHARMACIST INITIATED EMERGENCY CONTRACEPTION

    May 1, 2006, 00:00

  • PMC8 AN INTERACTIVE ECONOMIC MODEL FOR VACUUM ASSISTED CLOSURE THERAPY

    May 1, 2006, 00:00

  • PAR16 CAN OSTEOARTHRITIS PATIENTS EVALUATE TRADEOFFS BETWEEN NSAID RISKS AND BENEFITS?

    May 1, 2006, 00:00

  • PCV56 PERSISTENCE WITH NEWLY-INITIATED EXTENDED-RELEASE NIACIN VERSUS OTHER LIPID MODIFYING DRUG CLASSES IN CLINICAL PRACTICE

    May 1, 2006, 00:00

  • PAR13 A PROSPECTIVE STUDY COMPARING DRUG UTILIZATION PATTERNS AND COST OF TREATMENT OF PATIENTS FOR RHEUMATOID ARTHRITIS IN KERALA, INDIA

    May 1, 2006, 00:00

  • PCV49 PATIENT ADHERENCE TO AHA GUIDELINES PRE-AND POST AMI

    May 1, 2006, 00:00

  • PMH5 INCIDENT DIABETES ASSOCIATED WITH USE OF SECOND-GENERATION ANTIPSYCHOTIC (SGA) THERAPY-AN EVALUATION OF THE IMPACT OF DOSE AND TREATMENT INDICATION

    May 1, 2006, 00:00

  • PR1 A BAYESIAN ESTIMATION OF AN AVERAGE SF-6D PREFERENCE BASED SCORE FROM COMMONLY REPORTED SF-12 STATISTICS

    May 1, 2006, 00:00

  • PG15 COMPARING THE COST-EFFECTIVENESS OF THE INTERFERONS (IFNS) UTILIZED IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV)- A MODEL EVALUATING THE CLINICAL AND ECONOMIC IMPACT OF CURRENT TREATMENT OPTIONS

    May 1, 2006, 00:00

  • POS4 COMPARATIVE ANALYSIS OF HEALTH INSURANCE COST OF MEDIAL FEMORAL NECK FRACTURES WITH AND WITHOUT COMPLICATIONS ON A 2 YEARS FOLLOW UP

    May 1, 2006, 00:00

  • PGI16 TRENDS OF GASTRIC ACID-SUPPRESSIVE DRUG USE IN THE GENERAL PRACTICE OF UK FROM 1995 TO 2005

    May 1, 2006, 00:00

  • PMC18 THE PROLABELS DATABASE- A NEW ON-LINE TOOL TO EXPLORE THE WORDING AND TYPES OF PRO INCLUDED IN APPROVED MEDICINAL PRODUCTS LABELS

    May 1, 2006, 00:00

  • PUK3 ECONOMIC IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY-INSURED PERSONS ≥65 YEARS OF AGE WITH OVERACTIVE BLADDER

    May 1, 2006, 00:00

  • PCV22 INPATIENT MANAGEMENT OF TRANSMURAL AND SUBENDOCARDIAL ACUTE MYOCARDIAL INFARCTION (AMI)- DIFFERENCES IN RESOURCE USE AND COST

    May 1, 2006, 00:00

  • PR4 CONVERTING THE SCORES OF A CLINICAL INSTRUMENT FOR MEASURING PAIN TO A PREFERENCE BASED ONE

    May 1, 2006, 00:00

  • PCN37 ESTIMATION OF A SET OF PATIENT-BASED UTILITY WEIGHTS FOR THE FACT-G

    May 1, 2006, 00:00

  • POS9 TRENDS IN THE CLINICAL MANAGEMENT OF FRAGILE FRACTURE BEFORE AND AFTERTHE NEW HEDIS OSTEOPOROSIS MANAGEMENT MEASURE IN A MEDICARE POPULATION

    May 1, 2006, 00:00

  • PNL12 COST-EFFECTIVENESS OF ELETRIPTAN VERSUS SUMATRIPTAN- RESULTS FROM A RANDOMIZED, CONTROLLED TRIAL

    May 1, 2006, 00:00

  • PEY2 PREVALENCE AND DESCRIPTION OF TREATMENT WITH INTRAOCULAR PRESSURE LOWERING TOPICAL MEDICATIONS IN CONTINENTAL FRANCE

    May 1, 2006, 00:00

  • PDB21 ANTIDIABETIC MEDI CATION PRESCRIBING TRENDS IN FRANCE- EVIDENCE FROM PRIMARY CARE PHYSICIANS

    May 1, 2006, 00:00

  • POS7 CHANGES IN THE IMPAIRED ABILITYTO WORK IN PATIENTS UNDER 60 WITH MEDIAL FEMORAL NECK FRACTURE DURING 3 YEARS FOLLOW UP

    May 1, 2006, 00:00

  • PCV4 A NATIONAL STUDY PREDICTING THE INFLUENCE OF PAYMENT SOURCES ON THE THIAZIDE DIURETICS UTILIZATION FOR HYPERTENSION

    May 1, 2006, 00:00

  • PMH27 THE IMPACT OF PRESCRIBING OFF-LABEL MOOD STABILIZERS FOR PATIENTS WITH SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS- RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY

    May 1, 2006, 00:00

  • HP4 PRESCRIPTION DRUG INSURANCE AND ITS EFFECT ON UTILIZATION AND HEALTH OF THE ELDERLY

    May 1, 2006, 00:00

  • CV1 INCREMENTAL EXPENDITURE OF TREATING HYPERTENSION IN THE UNITED STATES

    May 1, 2006, 00:00

  • PDB35 TOPIRAMATE TREATMENT IMPROVES QUALITY OF LIFE (QOL)AND NERVE FUNCTION IN PATIENTS WITH DIABETIC NEUROPATHY (DN)

    May 1, 2006, 00:00

  • POT2 FATIGUE IN THE U.S. WORKFORCE- PREVALENCE AND COST OF LOST PRODUCTIVE WORK TIME

    May 1, 2006, 00:00

  • PDB23 EXTERNAL VALIDATION OF THE UKPDS OUTCOMES MODEL EQUATIONS (UKPDS 68), AND THE UKPDS RISK ENGINE EQUATIONS (UKPDS 56 AND 60) IN FORECASTING CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PMC9 THE USE OF QUINTILE ANALYSIS ASA MEASURE OF DISEASE SEVERITY- A COMPARISON WITHIN AND ACROSS DISEASES

    May 1, 2006, 00:00

  • PEY3 THE ECONOMIC IMPACT OF BLUE-LIGHT FILTERING INTRAOCULAR LENSES ON AGE-RELATED MACULAR DEGENERATION ASSOCIATED WITH CATARACT SURGERY

    May 1, 2006, 00:00

  • PMH43 RAMIFICATIONS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PCN36 DEVELOPING HEALTH STATE DESCRIPTIONS FOR METASTATIC COLORECTAL CANCER- QUALITATIVE STUDY

    May 1, 2006, 00:00

  • PDB37/DBI- PATIENT-REPORTED UTILITIES/DISUTILITIES ASSOCIATED WITH TREATMENTS FOR TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PIH7 APPROPRIATE MEDICATION PRESCRIBING FORTHE ELDERLY- PHYSICIAN CONFIDENCE AND KNOWLEDGE

    May 1, 2006, 00:00

  • What Decision-Makers Want and What They Have Been Getting

    May 1, 2006, 00:00

  • PNL30 COMPARISON OF HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN MULTIPLE SCLEROSIS- A REVIEW

    May 1, 2006, 00:00

  • PCN27 HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS

    May 1, 2006, 00:00

  • FP4 NATIONAL ESTIMATES AND ASSOCIATED FACTORS OF ANTIPSYCHOTIC USE IN AMBULATORY CARE FROM 1996 TO 2003

    May 1, 2006, 00:00

  • UR3 FACTORS ASSOCIATED WITH CARE SEEKING FOR OVERACTIVE BLADDER SYMPTOMS

    May 1, 2006, 00:00

  • PDB36 EQ-5D IN TYPE 2 DIABETES- RELATIONSHIPS WITH QUALITY OF LIFE AND COMORBID CONDITIONS

    May 1, 2006, 00:00

  • PUK13 GENERIC VS. DISEASE-SPECIFIC SATISFACTION MEASURES- SELECTING A SATISFACTION MEASURE FOR OVERACTIVE BLADDER STUDIES

    May 1, 2006, 00:00

  • ND4 IMPACT OF TOPIRAMATE FOR MIGRAINE PROPHYLAXIS ON WORKPLACE PRODUCTIVITY- RESULTS FROM TWO U.S. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIALS

    May 1, 2006, 00:00

  • PCV28 ECONOMIC EVALUATION OF AN INTERDISCIPLINARY APPROACH TO HEART FAILURE MANAGEMENT

    May 1, 2006, 00:00

  • ND3 A DESCRIPTION OF OFFICE VISIT RATESAND PRESCRIPTION USE FOR INSOMNIA AMONG RECIPIENTS OF A STATE MEDICAID PROGRAM

    May 1, 2006, 00:00

  • PCV15 ATRIAL VERSUS DUAL CHAMBER PACING IN SINUS NODE DISEASE

    May 1, 2006, 00:00

  • PRS5 RESOURCE USE AND COST OF HEALTHCARE SERVICES AMONG PATIENTS NEWLY DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS- EVIDENCE FROM A LARGE STATE MEDICAID PROGRAM

    May 1, 2006, 00:00

  • CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA

    May 1, 2006, 00:00

  • PDB28 DEVELOPMENT OF NEW INDICES OF GLYCEMIC CONTROL IN PATIENTS WITH DIABETES USING DIGITAL SIGNAL PROCESSING

    May 1, 2006, 00:00

  • PCN31 A METHOD TO REMOVE CONTINUOUS ENROLLMENT REQUIREMENT FROM PHARMAECONOMIC STUDIES

    May 1, 2006, 00:00

  • PMH6 NEW-ONSET DIABETES MELLITUS ASSOCIATED WITH USE OF ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIC PATIENTS IN TAIWAN

    May 1, 2006, 00:00

  • PMH1 CRITERIA FOR IDENTIFYING PATIENTS WITH DEMENTIA AND PREVALENCE ESTIMATES OF DEMENTIA AMONG INDIANA MEDICAID RECIPIENTS

    May 1, 2006, 00:00

  • PIH5 A SYSTEMATIC REVIEW OF ATROPHIC VAGINITIS TREATMENT, DURATION OF THERAPY, AND HEALTH CARE COSTS

    May 1, 2006, 00:00

  • PCN46 ONLINE REPORTING OFTOXICITY SYMPTOMS BY LUNG CANCER PATIENTS DURING CHEMOTHERAPY

    May 1, 2006, 00:00

  • PDB8 ECONOMIC IMPACT OF AUGMENTATION THERAPY IN TYPE 2 DIABETES PATIENTS INITIATED ON SULFONYLUREAS- A RETROSPECTIVE COHORT ANALYSIS

    May 1, 2006, 00:00

  • PDB1 RETROSPECTIVE STUDY OF INSULIN GLARGINE USE IN PREVIOUSLY INSULIN-NAIVE U.S. MANAGED CARE PATIENTS WITH TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PIN18 HOSPITAL LENGTH-OF-STAYAND COSTS ASSOCIATED WITH USE AND EARLIER INITIATION OF DROTRECOGIN ALFA (ACTIVATED) IN ADULT PATIENTS WITH THE HIGHEST PROPENSITY OF HAVING SEVERE SEPSIS

    May 1, 2006, 00:00

  • PCV66 A SYSTEMATIC REVIEW OF THE DISEASE-SPECIFIC AND THE GENERIC QUALITY-OF-LIFE INSTRUMENTS IN CONGESTIVE HEART FAILURE

    May 1, 2006, 00:00

  • PMH29 ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATION CLINICAL PRIOR AUTHORIZATION PROGRAM'S IMPACT ON PRESCRIPTION DRUG UTILIZATION AND COSTS

    May 1, 2006, 00:00

  • PAR6 MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS

    May 1, 2006, 00:00

  • PCN4 RETROSPECTIVE COHORT STUDY OF TAMOXIFEN TREATED BREAST CANCER PATIENTS ASSOCIATED WITH RISK OF ENDOMETRIAL CANCER

    May 1, 2006, 00:00

  • PMH37 COMPARING ADHERENCE AND PERSISTENCE WITH ANTIPSYCHOTIC THERAPY AMONG PATIENTS WITH BIPOLAR DISORDER

    May 1, 2006, 00:00

  • ND1 THE INDIRECT COST BURDEN OF MIGRAINE AMONG SEVERAL LARGE U.S. EMPLOYERS

    May 1, 2006, 00:00

  • PHP27 CLUSTER ANALYSIS OF STATE MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • PIH13 COMPLIANCE WITH PRESCRIBED ONCE A DAY PLACEBO IN ADOLESCENT HEALTHYVOLUNTEERS

    May 1, 2006, 00:00

  • PRO3 EVALUATION OF A PROGRAM TO IMPROVE ADHERENCE WITH PEGYLATED INTERFERON THERAPY- A PROPENSITY SCORE MATCHED RETROSPECTIVE COHORT ANALYSIS

    May 1, 2006, 00:00

  • PMC17 MULTI-METHOD QUALITATIVE APPROACH TO DEVELOP COMPREHENSIVE PATIENT-REPORTED OUTCOME MEASURES- AN EXAMPLE FROM DENTAL CARE

    May 1, 2006, 00:00

  • CS4 FREQUENCY AND COST OF DISABILITY AMONG EMPLOYED INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    May 1, 2006, 00:00

  • PHP6 BENEFICIARIES' OUT-OF-POCKET COSTS UNDER THE MEDICARE PRESCRIPTION DRUG BENEFIT- EVIDENCE FROM MEDICARE DISCOUNT DRUG CARD CLAIMS DATA

    May 1, 2006, 00:00

  • PMH41 PREDICTORS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PIH6 MEDICAL RESOURCE UTILIZATION IN DIAGNOSED PREMATURE EJACULATION PATIENTS

    May 1, 2006, 00:00

  • PNL3 HOSPITAL LENGTH OF STAY ASSOCIATED WITH ANTICONVULSANT UTILIZATION BY PATIENTS WITH SEIZURE DISORDERS IN THE U.S.

    May 1, 2006, 00:00

  • FP3 AN AUDIT OF 106 ECONOMIC ANALYSES CONTAINED IN AMCP DOSSIER SUBMISSIONS 2002-2005

    May 1, 2006, 00:00

  • PGI21 ADHERENCE AND RIBAVIRIN DOSE AS CRITICAL SUCCESS FACTORS TO THE CHRONIC HEPATITIS C (CHC) TREATMENT- A CROSS SECTIONAL EVALUATION IN BRAZIL

    May 1, 2006, 00:00

  • PCV51 OUTPATIENT DISCONTINUATION AND RESTARTING OF POST-MYOCARDIAL INFARCTION BETA-BLOCKERTHERAPY

    May 1, 2006, 00:00

  • FP2 COST-EFFECTIVENESS OF A GLAUCOMA-SCREENING PROGRAM- A MODEL EVALUATING THE RELATIVE CLINICAL AND ECONOMIC IMPACT IN COMMERCIAL VS. SENIOR MEMBER POPULATIONS

    May 1, 2006, 00:00

  • PMH33 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS PRESCRIBED ANTIPSYCHOTIC (AP) MONOTHERAPY IN TEXAS MEDICAID

    May 1, 2006, 00:00

  • PUK5 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS IN ANEMIC PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS

    May 1, 2006, 00:00

  • PMC24 BAYESIAN ESTIMATION OF COST-EFFECTIVENESS ADJUSTED FOR REAL WORLD CONSIDERING STATISTICAL ERRORS IN CLINICAL TRIALS

    May 1, 2006, 00:00

  • PCN16 ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS- A MEDICARE PERSPECTIVE

    May 1, 2006, 00:00

  • PMH12 AN ECONOMIC EVALUATION OF ATYPICAL ANTIPSYCHOTIC FOR BIPOLAR DISORDER IN THE NC MEDICAID PROGRAM

    May 1, 2006, 00:00

  • CS3 THE EFFECT OF ORGAN THREATENING AND MENTAL HEALTH CO-MORBIDITIES ON MEDICAL COSTS IN SYSTEMIC LUPUS ERYTHEMATOSUS

    May 1, 2006, 00:00

  • PMH47 THE MISSION IS REMISSION–HEALTH ECONOMIC CONSEQUENCES OF ACHIEVING REMISSION WITH ANTIDEPRESSANT TREATMENT FOR DEPRESSION

    May 1, 2006, 00:00

  • PGI14 COST-UTILITY OF A MODALITY OF “C” VIRUS HEPATITIS TREATMENT IN PATIENTS THAT DO NOT RESPOND TO INTERFERON PLUS RIBAVIRIN IN MEXICO

    May 1, 2006, 00:00

  • PMH19 ANTIPSYCHOTIC NON-ADHERENCE AND COSTS OF SHORT-TERM INPATIENT TREATMENT FOR SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PEY6 REAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE

    May 1, 2006, 00:00

  • PNL26 EXTENDING MATCHING ESTIMATORS OF CAUSAL EFFECTS TO CONSIDER UNOBSERVED VARIABLE BIAS- AN APPLICATION OF SENSITIVITY ANALYSIS

    May 1, 2006, 00:00

  • PRS2 EVALUATION OF TREATMENT PATTERNS AND HEALTH CARE COSTS AMONG COPD PATIENTS USING INHALED CORTICOSTEROIDS ORANTICHOLINERGIC AGENTS IN A MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PGI12 COST-UTILITY ANALYSIS OFTEGASEROD FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME

    May 1, 2006, 00:00

  • PCV68 BENEFICIAL IMPACT ON BLOOD PRESSURE CONTROL AMONG MEN PRESCRIBED SILDENAFIL CITRATE

    May 1, 2006, 00:00

  • PAR5 COST-EFFECTIVENESS OF RITUXIMAB AS A NEW TREATMENT MODALITY FOR RHEUMATOID ARTHRITIS IN GERMANY

    May 1, 2006, 00:00

  • PCN9 ECONOMIC EVALUATION OFANTIEMETIC REGIMENS FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

    May 1, 2006, 00:00

  • PMH23 HEALTH CARE RESOURCE UTILIZATION PRE/POST RISPERIDONE LONG-ACTING INJECTABLE TREATMENT INITIATION IN A MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PMH10 COST AND EFFECTIVENESS OF SWITCHING FROM RISPERIDONE TO OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PCV13 CLOPIDOGREL THERAPY AND HEALTH CARE COSTS FOLLOWING AN ACUTE CORONARY SYNDROME EVENT

    May 1, 2006, 00:00

  • CN1 ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS- A PRIVATE PAYER PERSPECTIVE

    May 1, 2006, 00:00

  • PMH34 DETERMINANTS IN ANTIDEPRESSANT TREATMENT SELECTION FOLLOWING THE INTRODUCTION OF DULOXETINE

    May 1, 2006, 00:00

  • CN3 COLONOSCOPY PROCEDURE RATES AMONG PRIVATE-PAY PATIENTS INCREASED SUBSTANTIALLY BETWEEN 2000 AND 2004

    May 1, 2006, 00:00

  • PMC23 NOT ALL PATIENTS ARE AVERAGE-THE IMPORTANCE OF RECOGNISING PATIENT HETEROGENEITY

    May 1, 2006, 00:00

  • PMH45 DURATION OF ANTIPSYCHOTIC SWITCHING PROCESS IN THE NATURALISTIC TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PAS9 THE PERFORMANCE OF BOOTSTRAPPING IN DISCRETE CHOICE MODELS

    May 1, 2006, 00:00

  • PHP25 HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PHARMACEUTICAL CARE- EVALUATING PHARMACIST'S KNOWLEDGE, UNDERSTANDING AND PERCEIVED BARRIERS IN PHARMACY PRACTICE

    May 1, 2006, 00:00

  • POB1 ASSOCIATION BETWEEN BMI AND HEALTH CARE EXPENDITURES USING THE 2002 MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2006, 00:00

  • PCN14 COST-EFFECTIVENESS OFTAXANES AS SECOND LINE AGENTS IN TREATMENT OF METASTATIC BREAST CANCER

    May 1, 2006, 00:00

  • PCV30 TREND ANALYSIS OF PRICE AND UTILIZATION OF STATIN DRUGS IN U.S. MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • HI3 THE EFFECTS OF STATIN (HMG-COA REDUCTASE INHIBITOR) COPAYMENTS AND STATIN ADHERENCE ON MEDICAL CARE OUTCOMES AND EXPENDITURES

    May 1, 2006, 00:00

  • AC4 OCCURRENCE OF THROMBOCYTOPENIA AFTER ORTHOPEDIC SURGERIES IN PATIENTS TREATED WITH FONDAPARINUX, DALTEPARIN, ENOXAPARIN OR UNFRACTIONATED HEPARIN

    May 1, 2006, 00:00

  • PCV42 PREDICTING HIGH COSTS IN CALIFORNIA MEDICAID PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)

    May 1, 2006, 00:00

  • Bringing Health Economic Modeling to the 21st Century

    May 1, 2006, 00:00

  • PCV52 MEDICATION ADHERENCE- PREDICTORS AND IMPACT ON HOSPITALIZATION RISK

    May 1, 2006, 00:00

  • PHP22 PRESCRIPTION DRUG PRICE COMPARISONS BETWEEN CANADIAN AND US ON-LINE PHARMACIES OVER A SIX-MONTH PERIOD

    May 1, 2006, 00:00

  • POS3 BUDGET IMPACT ANALYSIS OF BISPHOSPHONATES FOR FRACTURES IN POSTMENOPAUSAL WOMEN

    May 1, 2006, 00:00

  • PHP26 DEVELOPING A MEASURE OF PATIENT EMPOWERMENT TO BE APPLIED IN THE GENERAL COMMUNITY

    May 1, 2006, 00:00

  • PAS13 ASSOCIATION OF MEDICATION ADHERENCE WITH WORKPLACE PRODUCTIVITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ASTHMA

    May 1, 2006, 00:00

  • PHP3 IMPACT OF CONSUMER-DIRECTED HEALTH PLAN ON PHARMACY UTILIZATION

    May 1, 2006, 00:00

  • PCV44 THE CASE OF LI PI D-LOWERING THERAPY- A COMPARISON OF ADHERENCE MEASUREMENT METHODOLOGIES USING ADMINISTRATIVE CLAIMS DATA

    May 1, 2006, 00:00

  • HE2 ESTIMATING OUT-OF-POCKET PHARMACEUTICAL EXPENDITURES UNDERTHE NEW MEDICARE DRUG LAW FOR PATIENTS WITH MENTAL DISORDERS—AN ANALYSIS OF CLAIMS DATA FROM RETIREE MEDICAL PLANS

    May 1, 2006, 00:00

  • PMH24 INCREASING FORMULARY ACCESS TO INNOVATIVE DRUGS- EFFECTS ON THE TREATMENT FOR SCHIZOPHRENIA IN A MEDI-CAL POPULATION

    May 1, 2006, 00:00

  • PIH17 DEVELOPMENT OF A PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE FOR BENIGN PROSTATIC HYPERPLASIA (BPH-PSTQ)

    May 1, 2006, 00:00

  • PG19 COST-UTILITY-ANALYSIS OF PEGINTERFERON ALFA-2B PLUS RIBAVIRIN VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS INITIAL THERAPY FOR CHINESE NAIVE PATIENTS WITH CHRONIC HEPATITIS C

    May 1, 2006, 00:00

  • PUK4 ELEVATED INTACT PARATHYROID HORMONE LEVELSAND HEALTH CARE COSTS AND UTILIZATION- RETROSPECTIVE COHORT OF PATIENTS WITH CHRONIC KIDNEY DISEASE

    May 1, 2006, 00:00

  • PMH13 AN ECONOMIC COST ANALYSIS OF ATYPICAL ANTIPSYCHOTIC SINGLE TREATMENT FOR BIPOLAR DISORDER IN A MEDICAID PROGRAM

    May 1, 2006, 00:00

  • PNL32 EVALUATION OF THE IMPACT OF AN EMPLOYEE WORKSITE DISEASE MANAGEMENT PROGRAM FOR MIGRAINEURS ON WORK PRODUCTIVITY

    May 1, 2006, 00:00

  • PCV8 OUTCOMES OF CONGESTIVE HEART FAILURE INPATIENTS TREATED WITH NESIRITIDE

    May 1, 2006, 00:00

  • RS4 AN EVALUATION OF THE ASSOCIATION BETWEEN HEALTH CARE UTILIZATION AND USE OF SALMETEROL AMONG SUBJECTS WITH ASTHMA

    May 1, 2006, 00:00

  • PSU2 THE SHORT TERM COST-EFFECTIVENESS OF 45 SURGICAL INTERVENTIONS IN THE UK

    May 1, 2006, 00:00

  • PAR4 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS IN THE UK

    May 1, 2006, 00:00

  • PRS6 TOBACCO SMOKING AND DIRECT COSTS OF TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS

    May 1, 2006, 00:00

  • PMH46 HEALTH-RELATED QUALITY-OF-LIFE MEASURED BY EQ-5D IN PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE

    May 1, 2006, 00:00

  • PMC15 INTERNET-BASED UTILITY ELICITATION OF A GENERIC HEALTH STATE

    May 1, 2006, 00:00

  • PDB27 ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT DIABETES—COMPARISON OF RESULTS WITH AND WITHOUT PROPENSITY SCORING

    May 1, 2006, 00:00

  • PDB39 DIABETIC PATIENTS' PREFERENCE FOR INHALED INSULIN

    May 1, 2006, 00:00

  • PPN3 THE PRICING AND DISTRIBUTION OF REPACKAGED DRUGS- COST EFFECTS IN THE CALIFORNIA WORKERS' COMPENSATION SYSTEM

    May 1, 2006, 00:00

  • PIN2 COST COMPARISON OF A ONCE-DAILY PARENTERAL ANTIBIOTIC IN HOSPITAL SETTINGS- INFORMATION FROM THE SIDESTEP STUDY

    May 1, 2006, 00:00

  • PCV64 THE LEVEL AND LONG-TERM DYNAMICS OF THE QUALITY OF LIFE AS PREDICTORS OF ADHERENCE TO ROUTINE HYPERTENSION MANAGEMENT

    May 1, 2006, 00:00

  • PHP19 COST SAVINGS ASSOCIATED WITH TABLET SPLITTING PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING

    May 1, 2006, 00:00

  • PHP18 IMPACT OF STEPS (SAFE, THERAPEUTIC AND ECONOMIC PHARMACEUTICAL SELECTION) MODEL ON PRESCRIBING COSTS OF STATINS

    May 1, 2006, 00:00

  • PCN8 COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH URACIL-TEGAFUR, AN ORAL FLUOROPYRIMIDINE DERIVATIVE, IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER IN JAPAN

    May 1, 2006, 00:00

  • PCV67 PREDICTORS OF HIGH BLOOD PRESSURE KNOWLEDGE IN HYPERTENSIVE PATIENTS

    May 1, 2006, 00:00

  • PRO5 PHYSICIAN IMPRESSIONSAND USES OF PATIENT-REPORTED OUTCOMES DATA

    May 1, 2006, 00:00

  • PAR20 BENEFIT-RISK-COST TRADE-OFF ANALYSES USING PATIENT PREFERENCES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2006, 00:00

  • PCV11 EVALUATION OF A MAIL-BASED WARFARIN (COUMADIN®) PATIENT EDUCATION INITIATIVE IN A MANAGED CARE SETTING

    May 1, 2006, 00:00

  • PCN11 COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER

    May 1, 2006, 00:00

  • PAR10 COST-EFFECTIVENESS OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS- A PAN-EUROPEAN ANALYSIS

    May 1, 2006, 00:00

  • PCV29 ANALYSES FOR PRICE AND UTILIZATION OF CALCIUM CHANNEL BLOCKERS IN US MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • PCV9 CARDIOVASCULAR RISK PREDICTED BY ADHERENCE TO STATINS IN A MEDICAID POPULATION

    May 1, 2006, 00:00

  • PSK5 TREATMENT PATTERNS IN PATIENTS WITH SEVERE PSORIASIS

    May 1, 2006, 00:00

  • PCV60 IMPACT OF ADHERENCE TO ANTIHYPERLIPIDEMIC DRUGS ON TOTAL PHARMACY AND MEDICAL COSTS

    May 1, 2006, 00:00

  • PMH16 HEALTH CARE COSTS AND UTILIZATION PATTERNS OF INDIVIDUALS WITH GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED STATES

    May 1, 2006, 00:00

  • PMH38 ADHERENCE LEVELS AND DIFFERENTIAL USE OF MENTAL HEALTH SERVICES IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PMH4 META-ANALYSIS OF SNRIS, SSRIS, AND TCAS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER USING REMISSION AS THE CLINICAL OUTCOME

    May 1, 2006, 00:00

  • PCN42 PREDICTIVE VALUE OF SERIAL MEASUREMENTS OF QUALITY OF LIFE ON ALL-CAUSE MORTALITY IN PROSTATE CANCER PATIENTS- DATA FROM CAPSURE™

    May 1, 2006, 00:00

  • PCV32 DRUG PRICE AND UTILIZATION OF ACE INHIBITORS IN US MEDICAID POPULATION

    May 1, 2006, 00:00

  • PRO1 RESULTS OF ALTERNATIVE DEFINITIONS FOR STATIN REFILL COMPIANCE, PERSISTENCE AND GAPS IN A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2006, 00:00

  • PMC25 MEASURING SOCIAL PREFERENCES FOR EQ-5D HEALTH STATES- NEW SOLUTIONS TO OLD PROBLEMS

    May 1, 2006, 00:00

  • CS2 ECONOMIC BURDEN OF WORK LOSS AMONG SUFFERERS OF LYMPHATIC FILARIASIS- AN ERADICABLE GLOBAL HEALTH PROBLEM

    May 1, 2006, 00:00

  • PHP9 SUMMARY OF THE FIRST YEAR OF A DISEASE MANAGEMENT PROGRAM IN PATIENTS WITH BLEEDING DISORDERS

    May 1, 2006, 00:00

  • PUK1 PREVALENCE OF NEUROGENIC BLADDER IN PATIENTS WITH VARIOUS NEUROLOGIC DISORDERS IN THE UNITED STATES

    May 1, 2006, 00:00

  • POB6 SELF-IMAGE SCALE- A PRAGMATIC EVALUATION

    May 1, 2006, 00:00

  • POS11 THE USE OF INDIVIDUAL RISKS RATHER THAN POPULATION AVERAGES IN COST-EFFECTIVENESS MODELING

    May 1, 2006, 00:00

  • PCV31 DRUG PRICE AND UTILIZATION OF BETA BLOCKERS IN US MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • PIN4 ECONOMIC ANALYSIS OF LATENT TUBERCULOSIS INFECTION (LTBI) SCREENING IN MILITARY RECRUITS- QUANTIFERON®-TB GOLD IN-TUBE (QFT-GIT) VERSUS TUBERCULIN SKIN TESTING (TST)

    May 1, 2006, 00:00

  • UR4 THE COST-EFFECTIVENESS OF VARIOUS TREATMENT STRATEGIES FORABNORMAL UTERINE BLEEDING

    May 1, 2006, 00:00

  • PMC2 HEALTH CONDITIONS IN POSTMENOPAUSAL WOMEN AND IMPLICATIONS FOR THE DESIGN OF CLINICAL TRIALS OF AROMATASE INHIBITORS

    May 1, 2006, 00:00

  • POB9 EFFECT OF RIMONABANT ON QUALITY OF LIFE IN OVERWEIGHT/OBESE PATIENTS

    May 1, 2006, 00:00

  • PIN21 USE OF EVIDENCE BASED MODELS TO DEMONSTRATE THE LONG-TERM CLINICAL BENEFITS OF HPV VACCINATION

    May 1, 2006, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165 (current)
  • 166
  • 167
  • 168
  • 169
  • 170
  • »